BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15231861)

  • 21. 5-Fluorouracil, high-dose folinic acid, and mitomycin C combination chemotherapy in advanced gastrointestinal adenocarcinomas. A pilot study.
    Becouarn Y; Brunet R; Bussières E; Marée D
    Oncology; 1988; 45(4):269-72. PubMed ID: 3133620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: preliminary results.
    Marini G; Marpicati P; Zaniboni A; Cervi GC; Gorni F; Simoncini E
    Chemioterapia; 1985 Apr; 4(2):135-8. PubMed ID: 3874000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
    Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E; Zipoli T; Gonzalves L
    J Infus Chemother; 1996; 6(1):43-6. PubMed ID: 8748007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [5-fluorouracil, high dose folinic acid and mitomycin C in the treatment of advanced digestive cancers].
    Seitz JF; Diaw A; Giovannini M; Perrier H; Gouvernet J
    Bull Cancer; 1994 Feb; 81(2):134-7. PubMed ID: 7894119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damage.
    Ceyhan C; Meydan N; Barutca S; Tekten T; Onbasili AO; Ozturk B; Unal S
    Echocardiography; 2005 Mar; 22(3):233-8. PubMed ID: 15725158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of methotrexate serum level achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil.
    Comella P; Palmieri G; Beneduce G; Casaretti R; Daponte A; Gravina A; Frasci G; Biondi E; Comella G
    Oncology; 1996; 53(3):198-203. PubMed ID: 8643221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
    Ducreux M; Ychou M; Seitz JF; Bonnay M; Bexon A; Armand JP; Mahjoubi M; Méry-Mignard D; Rougier P
    J Clin Oncol; 1999 Sep; 17(9):2901-8. PubMed ID: 10561369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QT dispersion, QT maximum and risk of cardiac death in the Caerphilly Heart Study.
    Sheehan J; Perry IJ; Reilly M; Salim A; Collins M; Twomey EM; Daly A; Loingsigh SN; Elwood P; Ben-Shlomo Y; Davey-Smith G
    Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):63-8. PubMed ID: 15167208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
    Machover D; Grison X; Goldschmidt E; Zittoun J; Lotz JP; Metzger G; Richaud J; Hannoun L; Marquet J; Guillot T
    J Natl Cancer Inst; 1992 Mar; 84(5):321-7. PubMed ID: 1738182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.
    Lin CC; Cheng AL; Hsu CH; Lu YS; Hsu C; Yeh KH; Wu CY; Huang CS; Yang CH
    Anticancer Res; 2007; 27(1B):641-5. PubMed ID: 17348454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
    Hartmann JT; Pintoffl JP; Al-Batran SE; Quietzsch D; Meisinger I; Horger M; Nehls O; Bokemeyer C; Königsrainer A; Jäger E; Kanz L
    Onkologie; 2007 May; 30(5):235-40. PubMed ID: 17460417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
    Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
    Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
    Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.